Buy Zeposia for 65% off US Zeposia prices. European product.
Non-english packaging - English label and English insert included. Plan in advance - allow us 7 days to ship your medicine
Manufacturer for all Europe product: Celgene Distribution B.V. Orteliuslaan 1000 3528 BD Utrecht Netherlands
Information about Zeposia (Ozanimod)
Zeposia is an oral medication containing Ozanimod, a selective sphingosine-1-phosphate (S1P) receptor modulator. It works by selectively targeting and modulating specific receptors on immune cells, reducing their ability to migrate to the central nervous system, which plays a key role in autoimmune diseases. Zeposia is primarily used in the treatment of relapsing forms of multiple sclerosis (MS) and ulcerative colitis (UC).
Product Highlights
- Zeposia is indicated for the treatment of adults with relapsing forms of multiple sclerosis, including relapsing-remitting MS. It helps reduce the frequency of MS relapses and slow the progression of disability.
- Zeposia is used to treat moderate to severe active UC in adults who have not responded to or are intolerant to other therapies.
Key Ingredient
Key Benefits
- Zeposia has been shown to reduce the frequency of relapses in people with relapsing forms of MS and can help slow disease progression.
- It helps in managing moderate to severe active UC by reducing inflammation and improving symptoms like diarrhea, bleeding, and abdominal discomfort.
- Zeposia offers the convenience of a once-daily oral pill, which is more convenient compared to some injectable or infusion-based therapies for MS and UC.
- By modulating the immune system, Zeposia reduces the immune cells' ability to attack the central nervous system in MS and the gastrointestinal system in UC.
Direction of Use
- Zeposia is typically taken once daily, with or without food.
- The treatment typically begins with a titration dose for the first few days, gradually increasing to the standard daily dose, as determined by the healthcare provider.
- The healthcare provider will determine the appropriate dosage and treatment duration based on the individual’s condition and response to the medication.
Safety Concerns
- Zeposia can increase the risk of infections because it affects the immune system. Patients should be monitored for signs of infections such as upper respiratory infections or urinary tract infections.
- The medication can cause a slow heart rate (bradycardia) when starting treatment, so patients are monitored for heart rhythm issues, especially during the first dose titration.
- Liver function tests should be performed regularly, as Zeposia can impact liver enzymes.
- There is a risk of macular edema (swelling in the eye), which may affect vision. Regular eye exams are recommended during treatment.
- Zeposia is contraindicated in pregnancy because it may harm the developing fetus. Women of childbearing age should use effective contraception during treatment and for 3 months after stopping the medication.
Avoid Zeposia (Ozanimod) If
- You are pregnant or plan to become pregnant, as Zeposia can harm the unborn baby.
- You have a history of severe liver problems or elevated liver enzymes.
- You have a history of macular edema (eye swelling).
- You have an active infection, including tuberculosis (TB), as the medication can suppress the immune system.
- You have severe cardiovascular conditions, especially a history of heart rhythm problems or heart attack.
- You are allergic to Ozanimod or any other ingredient in Zeposia.
- You are currently taking certain other medications, such as anti-arrhythmic drugs, which can interact negatively with Zeposia.
